PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT06177457
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
🇺🇸Yale University/Magnetic Resonance Research Center (MRRC), New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06172348
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
- Conditions
- COVID-19Coronavirus Disease 2019Influenza
- Interventions
- Biological: COVID-19 Vaccine
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT06163677
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- Conditions
- Vitiligo
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT06163326
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
🇺🇸Alpesh D. Desai, DO PLLC, Houston, Texas, United States
🇯🇵Nagoya City University Hospital, Nagoya, Aichi, Japan
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT06153758
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇫🇷
Hôpital NOVO, Pontoise, Val-d'oise, France
🇺🇸Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Novel hormonal therapy
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2313
- Registration Number
- NCT06151418
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT06137729
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo for PF-07868489
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT06137742
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT06140290
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium